Compass Therapeutics (CMPX) Non-Current Debt (2019 - 2020)
Compass Therapeutics (CMPX) posted Non-Current Debt of $1.9 million for Q4 2020, down 49.95% sequentially from $3.7 million in Q3 2020, and down 79.91% YoY from $9.3 million in Q1 2020.
Compass Therapeutics (CMPX) Non-Current Debt (2019 - 2020) Analysis & Trends
Compass Therapeutics has reported Non-Current Debt for 2 years, with the latest figure at $1.9 million in Q4 2020.
- Quarterly Non-Current Debt fell 79.91% year-over-year to $1.9 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $1.9 million (down 79.91% YoY) and the FY2020 annual result came in at $1.9 million, down 79.91% from the prior year.
- Non-Current Debt declined to $1.9 million in Q4 2020 per CMPX's latest filing, from $3.7 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $9.3 million in Q4 2019 and troughed at $1.9 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Compass Therapeutics | 405.20 Mn | 405.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 1.87 Mn |
| Sep 30, 2020 | 3.73 Mn |
| Jun 30, 2020 | 5.59 Mn |
| Dec 31, 2019 | 9.29 Mn |